In the latest trading session, 0.43 million ITeos Therapeutics Inc (NASDAQ:ITOS) shares changed hands as the company’s beta touched 1.39. With the company’s most recent per share price at $16.00 changing hands around $0.01 or 0.05% at last look, the market valuation stands at $584.26M. ITOS’s current price is a discount, trading about -17.19% off its 52-week high of $18.75. The share price had its 52-week low at $8.20, which suggests the last value was 48.75% up since then. When we look at ITeos Therapeutics Inc’s average trading volume, we note the 10-day average is 0.43 million shares, with the 3-month average coming to 354.26K.

Analysts gave the ITeos Therapeutics Inc (ITOS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended ITOS as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. ITeos Therapeutics Inc’s EPS for the current quarter is expected to be -0.89.

ITeos Therapeutics Inc (NASDAQ:ITOS) trade information

Instantly ITOS is in green as seen in intraday trades today. With action -1.55%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 46.10%, with the 5-day performance at -1.55% in the red. However, in the 30-day time frame, ITeos Therapeutics Inc (NASDAQ:ITOS) is 10.33% up. Looking at the short shares, we see there were 2.5 million shares sold at short interest cover period of 9.07 days.

The consensus price target for the stock as assigned by Wall Street analysts is 38.5, meaning bulls need an upside of 58.44% from its recent market value. According to analyst projections, ITOS’s forecast low is 31 with 46 as the target high. To hit the forecast high, the stock’s price needs a -187.5% plunge from its current level, while the stock would need to soar -93.75% for it to hit the projected low.

ITeos Therapeutics Inc (ITOS) estimates and forecasts

Data shows that the ITeos Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 38.51% over the past 6 months, a -33.65% in annual growth rate that is considerably lower than the industry average of 17.40%. Year-over-year growth is forecast to reach 263.90% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 16.67M.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -40.62%. The 2024 estimates are for ITeos Therapeutics Inc earnings to decrease by -13.92%.

ITOS Dividends

ITeos Therapeutics Inc is expected to release its next quarterly earnings report on 2024-Nov-05.

ITeos Therapeutics Inc (NASDAQ:ITOS)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.70% of ITeos Therapeutics Inc shares while 103.08% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 103.80%. There are 103.08% institutions holding the ITeos Therapeutics Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 10.4094% of the shares, roughly 3.73 million ITOS shares worth $55.37 million.

RA CAPITAL MANAGEMENT, L.P. holds the second largest percentage of outstanding shares, with 9.8129% or 3.52 million shares worth $52.2 million as of 2024-06-30.

Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 1.27 shares estimated at $20.26 million under it, the former controlled 3.47% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 1.95% of the shares, roughly 713.65 shares worth around $11.4 million.